Search research articles
Contact Us
Filters
Showing results (61-70 of 109) with videos related to
Page
of 11
Sort By:
JCO Precision Oncology
|
February 12, 2025
Cancer Susceptibility Gene Testing in Patients With Pancreatic Ductal Adenocarcinoma: Implementation in a Cancer Center Oncology Clinic
Hassan Sinan, Dea Cunningham, Emy Abou Sleiman, et al.
Cancer Research Communications
|
August 30, 2023
Gemcitabine, Docetaxel, Capecitabine, Cisplatin, Irinotecan as First-line Treatment for Metastatic Pancreatic Cancer
H Catherine Wilbur, Jennifer N Durham, Su Jin Lim, et al.
JCO Precision Oncology
|
June 8, 2022
Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures
Kabir Mody, Prerna Jain, Sherif M El-Refai, et al.
Cancer Chemotherapy and Pharmacology
|
June 22, 2022
A phase Ib study of Oraxol (oral paclitaxel and encequidar) in patients with advanced malignancies
Wen Wee Ma, Jenny J Li, Nilofer S Azad, et al.
Oncotarget
|
April 29, 2017
Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer
Mark Yarchoan, Melinda C Myzak, Burles A Johnson, et al.
Clinical and Translational Science
|
August 2, 2020
A Phase I Study of Dinaciclib in Combination With MK-2206 in Patients With Advanced Pancreatic Cancer
Adrian G Murphy, Marianna Zahurak, Mirat Shah, et al.
Clinical and Translational Science
|
April 3, 2021
A phase 2 trial of gemcitabine and docetaxel in patients with metastatic colorectal adenocarcinoma with methylated checkpoint with forkhead and ring finger domain promoter and/or microsatellite instability phenotype
Marina Baretti, Enusha Karunasena, Marianna Zahurak, et al.
Biorxiv : the Preprint Server for Biology
|
August 7, 2023
ME3BP-7 is a targeted cytotoxic agent that rapidly kills pancreatic cancer cells expressing high levels of monocarboxylate transporter MCT1
Jordina Rincon-Torroella, Marco Dal Molin, Brian Mog, et al.
Cancers
|
June 2, 2021
Clinical Predictors of Early Trial Discontinuation for Patients Participating in Phase I Clinical Trials in Oncology
Joeri A J Douma, Laurien M Buffart, Ramy Sedhom, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 31, 2014
A Phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy in patients with advanced solid malignancies and peritoneal carcinomatosis
Kim A Reiss, Joseph M Herman, Marianna Zahurak, et al.
Page
of 11
Search research articles
Search
Showing results (61-70 of 109) with videos related to
Sort By:
Page
of 11
JCO Precision Oncology
|
February 12, 2025
Cancer Susceptibility Gene Testing in Patients With Pancreatic Ductal Adenocarcinoma: Implementation in a Cancer Center Oncology Clinic
Hassan Sinan, Dea Cunningham, Emy Abou Sleiman, et al.
Cancer Research Communications
|
August 30, 2023
Gemcitabine, Docetaxel, Capecitabine, Cisplatin, Irinotecan as First-line Treatment for Metastatic Pancreatic Cancer
H Catherine Wilbur, Jennifer N Durham, Su Jin Lim, et al.
JCO Precision Oncology
|
June 8, 2022
Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures
Kabir Mody, Prerna Jain, Sherif M El-Refai, et al.
Cancer Chemotherapy and Pharmacology
|
June 22, 2022
A phase Ib study of Oraxol (oral paclitaxel and encequidar) in patients with advanced malignancies
Wen Wee Ma, Jenny J Li, Nilofer S Azad, et al.
Oncotarget
|
April 29, 2017
Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer
Mark Yarchoan, Melinda C Myzak, Burles A Johnson, et al.
Clinical and Translational Science
|
August 2, 2020
A Phase I Study of Dinaciclib in Combination With MK-2206 in Patients With Advanced Pancreatic Cancer
Adrian G Murphy, Marianna Zahurak, Mirat Shah, et al.
Clinical and Translational Science
|
April 3, 2021
A phase 2 trial of gemcitabine and docetaxel in patients with metastatic colorectal adenocarcinoma with methylated checkpoint with forkhead and ring finger domain promoter and/or microsatellite instability phenotype
Marina Baretti, Enusha Karunasena, Marianna Zahurak, et al.
Biorxiv : the Preprint Server for Biology
|
August 7, 2023
ME3BP-7 is a targeted cytotoxic agent that rapidly kills pancreatic cancer cells expressing high levels of monocarboxylate transporter MCT1
Jordina Rincon-Torroella, Marco Dal Molin, Brian Mog, et al.
Cancers
|
June 2, 2021
Clinical Predictors of Early Trial Discontinuation for Patients Participating in Phase I Clinical Trials in Oncology
Joeri A J Douma, Laurien M Buffart, Ramy Sedhom, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 31, 2014
A Phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy in patients with advanced solid malignancies and peritoneal carcinomatosis
Kim A Reiss, Joseph M Herman, Marianna Zahurak, et al.
Page
of 11